NB 1001

Drug Profile

NB 1001

Alternative Names: GLP-1-XTEN; NB1001; XTEN™-GLP-1

Latest Information Update: 02 Dec 2016

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Amunix
  • Developer Naia Limited
  • Class Antihyperglycaemics
  • Mechanism of Action Glucagon like peptide 1 receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Short bowel syndrome
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Short bowel syndrome
  • Discontinued Type 2 diabetes mellitus

Most Recent Events

  • 06 Apr 2017 Naia Rare Diseases intends to launch NB 1001 for Short bowel syndrome in 2019 (Naia Rare Diseases website, April 2017)
  • 30 Nov 2016 Naia limited files an IND application with the US FDA for a phase Ib trial in Short bowel syndrome
  • 26 Jan 2016 Discontinued - Phase-I for Type-2 diabetes mellitus in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top